A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2016
At a glance
- Drugs CPI 0610 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Constellation Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 22 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2019.
- 22 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2018.